Shots:

• BeiGene to receive $150M and regains WW rights for tislelizumab with their mutual termination of WW development & commercialization agreement with Celgene- following the pending acquisition of Celgene by BMS
• In Jul’17- BeiGene granted exclusive WW rights (Ex- Asia) of tislelizumab for solid tumor and retained global rights for hematology & solid tumor in Asia. Additionally- BeiGene got exclusive commercialization rights for Celgene’s Abraxane- Revlimid- Vidaza in China which is unaffected with the termination deal of tislelizumab
• Tislelizumab (BGB-A317) is an anti-PD-1 antibody- targeting IgG4- minimizing the binding of FcγR on macrophages. NMPA has accepted its NDA for tislelizumab in patients with R/R cHL & LA or metastatic UC and has received PR for R/R cHL filing

Ref: BeiGene | Image: Chemistry World